摘要
目的:检测肿瘤相关巨噬细胞(TAM)分子表面标志物CD68、CD206在胃肠道弥漫大B细胞淋巴瘤(PGI-DLBCL)初诊和首次复发的表达变化,分析其变化与临床相关参数的关系,探讨TAM的极化在PGI-DLBCL复发中的作用。方法:收集28例PGI-DLBCL患者初诊和首次复发后淋巴瘤标本,采用免疫组织化学法分别检测TAM的分子标志物CD68和CD206的表达变化。根据CD68和CD206初诊至首次复发后表达的变化,将28例患者分为"增强"、"稳定"和"减弱"3种情况,分析其变化与临床病理参数、疾病复发的相关性。结果:CD68和CD206不同程度表达的病例所占比例间存在显著差异(P<0.05),且CD68和CD206间存在一定相关性(P=0.008)。CD68和CD206表达变化与患者年龄、性别、分期、有无B症状、病理类型、ECOG评分和IPI评分无关,CD206的表达变化与原发部位有关(P<0.05)。CD68(P=0.23)和CD206 (P=0.818)变化与肿瘤复发时间无关。结论:M2-TAM的极化促进了PGI-DLBCL复发,可能成为预测PG-DLBCL复发的相关指标。
Objective:To detect the change in expression of the tumor associated macrophage(TAM)markers CD68 and CD206 from first diagnosis to first relapse of primary gastrointestinal diffuse large B cell lymphoma(PGI-DLBCL),analyze the correlation between the changes and related clinical parameters,and explore the significance of polarization of TAM in treating the relapse.Methods:Lymphomas from 28 PGI-DLBCL patients at first diagnosis and first relapse were collected and molecular markers CD68 and CD206 were measured by immunohistochemical assay.Based on the change of CD68 and CD206,patients were categorized into three types:"increased","stable"and"decreased".The ratio of cases with different expression level of CD68 and CD206 was compared,and the correlation among the changes,related clinical parameters and the relapse were analyzed.Results:Significant differences in ratio of cases with different expression level of CD68 and CD206 were observed(P<0.05)and there was a correlation between CD68 and CD206(P=0.008).CD68 and CD206 expression showed no correlation with age,gender,stage,B symptoms,pathological type,ECOG score,or IPI scores,while CD206 expression had a positive correlation with primary site(P<0.05).There was no correlation between the changes and time to relapse(CD68:P=0.23 and CD206:P=0.818)Conclusion:Our study suggest that polarization of M2-TAM can promote the relapse of PGI-DLBCL,and it may be an important indicator of relapse of PGI-DLBCL.
作者
孟娟
高元慧
徐海霞
王美清
陈正义
MENG Juan;GAO Yuan-hui;XU Hai-xia;WANG Mei-qing;CHEN Zheng-yi(Department of Oncology,Affiliated Haikou Hospital of Xiangya Medical College of Central South University,Haikou 570208,China;Center Laboratory,Affiliated Haikou Hospital of Xiangya Medical College of Central South University,Haikou 570208,China;Pathology Department,Affiliated Haikou Hospital of Xiangya Medical College of Central South University,Haikou 570208,China;Gastroenterology Department,Affiliated Haikou Hospital of Xiangya Medical College of Central South University,Haikou 570208,China)
出处
《海南医学院学报》
CAS
2019年第5期347-350,357,共5页
Journal of Hainan Medical University
基金
2016年海南省卫计委科研项目-1601320671A2001~~
